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 1 
BRIEF OF AMICUS CURIAE UNIVERSITIES ALLIED FOR ESSENTIAL 
MEDICINES IN SUPPORT OF PLAINTIFFS-APPELLEES 
 
INTEREST OF AMICUS CURIAE 
 Universities Allied for Essential Medicines (“UAEM”) is an international 
nonprofit organization for university students advocating increased innovation and 
access to medicines and other health-related technologies.  UAEM works to 
promote affordable global access to essential medicines developed from university 
research.  More than one quarter of all gene patents are assigned to universities, 
and nearly two thirds of all gene patents are the result of publicly funded research.  
(A168, A14565.)  Accordingly, UAEM is particularly concerned with the negative 
impact of gene patents on the public’s ability to afford and utilize essential medical 
diagnostics and treatments for widespread disease prevention. 
AUTHORITY TO FILE 
All parties have consented to the filing of this amicus brief by UAEM.  As a 
result, in accordance with Federal Rule of Appellate Procedure 29(a), no motion 
for leave to file has been submitted with this brief.  
UAEM has no commercial interest in the parties to this action.  No part of 
this brief was authored by a party’s counsel nor did any party or a party’s counsel 
contribute money that was intended to fund preparation or submission of this brief.  
No person, other than the amicus curiae, UAEM, contributed money to the 
preparation and submission of this brief. 
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INTRODUCTION 
 The patents-in-suit are based on research performed at the publicly funded 
University of Utah (“UT”), using federal funding from the National Institute for 
Environmental Health Sciences (“NIEHS”), a subdivision of the National Institutes 
of Health (“NIH”).  UT obtained ownership over the patents-in-suit gene 
sequences by exercising its rights under the Bayh-Dole Act.  
The patent claims-at-issue are directed to two human genes—BRCA1 and 
BRCA2—that play a critical role in determining an individual’s susceptibility to 
breast cancer. Isolated genes are solely a product of nature, and thus should not be 
patented.  Diamond v. Chakrabarty, 447 U.S. 303 (1980). The process of isolating 
a gene requires only the application of well-understood scientific principles.  
(A2443-45.)  Research universities and UAEM members implement these 
scientific principles worldwide and on a daily basis.  Id.  The claims-at-issue do 
not use any novel approach that could be the basis for the patents. 
Even when a gene’s entire function has not yet been discovered, gene 
patents remove the gene from public domain, therefore stifling the competitive 
biotechnology research upon which collective understanding, innovation, and 
development of treatments depend.  A recent study on the effects of gene patents 
found a thirty-percent drop in subsequent scientific development outcomes for a 
genetic disease after a patent was granted on the targeted gene.  (A7062-65.)  
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Respected scientists including NIH Director, Francis Collins, and UAEM Advisory 
Board Member, Dr. John Sulston, have cautioned that gene patents place 
“unnecessary toll booths on the road to discovery.”  Alan E. Guttmacher & Francis 
S. Collins, Genomic Medicine—A Primer, 347 NEW. ENG. J. MED. 1512, 1514 
(2002);  See also (A2446-48.).   
Knowledge of a gene’s purpose and the existence of mutations are critical 
facts researchers use to develop new diagnostic and treatment methodologies.  The 
essential first steps to making such discoveries involve the identification and 
characterization of the gene.  UAEM is deeply troubled that the BRCA patent 
claims-at-issue remove essential facts from the realm of public use, particularly 
when the discovery of those facts was funded by the public, and took place at a 
public university.  The removal of these facts from the public commons 
dramatically restricts the ability of future university researchers to develop new 
clinical tests and novel pharmaceuticals.  
The district court properly found the BRCA patent claims-at-issue to be 
invalid, and UAEM urges the Court to uphold that decision.  The invalidation of 
the BRCA patent claims removes an unwarranted bottleneck limiting other 
researchers from additional innovation and discovery.  By upholding the district 
court’s decision, this Court can liberate the BRCA genes from exclusive control as 
the scientific community continues to discover their complexities.  Retaining these 
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invalid gene claims will create exclusive rights with unknown breadth and 
significance, which will impede the creation of novel products and the discovery of 
additional effects.  
The BRCA1/2 gene patents are especially onerous.  Defendants-Appellants 
obtained an exclusive license for the patents-at-issue and they have used those 
patents to prevent others from developing additional tests for the presence of 
mutations in the BRCA genes.  Defendants-Appellants have also resisted others’ 
attempts to independently verify the accuracy of BRCA1/2 tests, despite a study 
reported in the Journal of the National Cancer Institute which found Defendants-
Appellants’ test failed to find up to twenty percent of known BRCA1 mutations.  
Steve Benowitz, French Challenge to BRCA1 Patent Underlies European 
Discontent, 94 J. NAT’L CANCER INST. 2, 80 (2002).  In addition to the failure to 
find up to twenty-percent of known mutations, one study found that the test had a 
twelve percent error rate in correctly finding the mutations. Tom Walsh, et. al., 
Spectrum of Mutations in BRCA1, BRCA2, CHECK2, and TP53 in families at High 
Risk of Breast Cancer, 295 JAMA 1369, 1386 (2006). 
In addition, Defendants-Appellants have used their patent-monopoly to stifle 
continuing research on specific BRCA mutations that are more prevalent in 
minority groups.  Defendants-Appellants’ test has a higher rate of error for women 
of non-European ancestry than those of a Caucasian background.  (A1059; A3205-
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06.)  However, women who receive a questionable result from Defendants-
Appellants’ test for the cancer-causing version of BRCA genes, cannot obtain a 
second opinion based on a different BRCA genetic test as Defendant-Appellants 
are the exclusive provider of all BRCA tests.  (A160; A2652; A2772; A2937-38; 
A2982-83; A3037-38; A3065 A3072-73; A3077.)  This concern is especially 
troubling when the sole test available for BRCA1/2 mutations by Myriad is shown 
to be flawed. Steve Benowitz, French Challenge to BRCA1 Patent Underlies 
European Discontent, 94 J. NAT’L CANCER INST. 2, 80 (2002).  
Defendants-Appellants’ hoarding of the BRCA1/2 genes for pecuniary 
benefit is particularly evident from its original exclusion of six co-scientist 
contributors at NIEHS from the patents-in-suit.  (A143-44.)  Only after NIH 
maintained that its scientists conducted some of the most important work leading 
up to the sequencing of the gene did Myriad agree to include the names of the 
NIEHS researchers as inventors on its patent application and deserving of (as of 
2005, yet unpaid) royalties.  Id.  
UAEM believes that the BRCA gene patents now controlled by Myriad fail 
to promote the progress of science embedded in the Constitutional rationale of the 
Patent Act.  Myriad’s monopoly over research on these naturally occurring genes 
has not led to greater knowledge of the BRCA1/2 genes, but has instead led 
directly to a decrease in information concerning these genes because further 
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research results cannot be made publicly available due to Myriad’s issuance of 
cease-and-desist letters to scientists and decision to preclude all research into these 
genes.  Myriad’s monopoly over the BRCA 1/2 genes has therefore impeded the 
progress of science. (A163; A2672-74; A7271-73). 
UAEM’s members are committed to ensuring that the public receives the 
benefits of the research performed at our universities, particularly research 
conducted with the use of public funds.  UAEM members conduct research and 
pursue careers in medicine and public health, and the claims-at-issue hinder 
research, medical training, and collaboration within the scientific community by 
preventing access to these building-block scientific facts.  Moreover, Defendants-
Appellants’ monopoly increases costs of the research and treatment of genetic 
diseases.  The BRCA gene patents thus limit access to essential information which 
stands as the foundation to further genetic research by universities.  
In light of the foregoing facts, UAEM files as amicus curiae in support of 
Plaintiffs-Appellees.  
ARGUMENT 
I. THE DISTRICT COURT PROPERLY EXERCISED ITS DUTY TO 
DETERMINE PATENT ELIGIBILTY 
 
Article 1, Section 8, Clause 8 of the U.S. Constitution allows Congress to 
create laws to promote the progress of science and useful arts by allowing 
inventors to have a limited monopoly over their discoveries. U.S. CONST., art. 1, § 
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8, cl. 8.    The Patent Act creates a quid-pro-quo for the express purpose of 
advancing the “Progress of Science and useful Arts.”  However, the 
“embarrassment of an exclusive patent” is a special legal privilege justified only 
because such “monopolies of invention” serve the “benefit of society.”  Graham v. 
John Deere Co., 383 U.S. 1, 7-10 (1966) (quoting Thomas Jefferson). The Court 
has repeatedly held: “Congress may not authorize the issuance of patents whose 
effect is to remove existent knowledge from the public domain, or to restrict free 
access to materials already available.” John Deere Co., 383 U.S. at 5.  By creating 
monopolies that prohibit all others from creating the same effect or process by any 
means whatsoever, a patent discourages scientific progress in contravention of the 
avowed language policy of the Patent Act.  Le Roy v. Tatham, 55 U.S. 156, 175 
(1853)  
Not all discoveries are eligible for patent protection.  The claims-at-issue 
restrict access to basic tools of scientific research and thus “impede rather than 
promote the Progress of Science and the useful Arts.” Ass’n for Molecular 
Pathology v. U.S. Patent and Trademark Office.  702 F.Supp.2d 181, 219 
(S.D.N.Y. 2010) (09 Civ. 4515) (quoting Lab. Corp. of Am. Holdings v. Metabolite 
Labs., Inc., 548 U.S. 124, 126-27 (2006) (Breyer, J., dissenting) (quotation marks 
omitted)).  The district court properly found these claims to be invalid under 35 
U.S.C. § 101, and that decision should be affirmed. 
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II. PRODUCTS OF NATURE, LAWS OF NATURE, NATURAL 
PHENOMENA, AND ABSTRACT IDEAS ARE NOT ELIGIBLE FOR 
PATENT PROTECTION 
 
While the Court has consistently recognized that Title 35 must be broadly 
interpreted to accomplish Congress’ design of encouraging innovation, three 
specific types of claims have been categorically removed from the scope of patent 
protection: “the laws of nature, physical phenomena, and abstract ideas.” Diamond 
v. Chakrabarty, 447 U.S. 303, 309 (1980); see also, Diamond v. Diehr, 450 U.S. 
175, 185 (1981).  Further, in determining patent eligibility, the Supreme Court has 
eschewed bright line tests, instead providing the lower courts with boundary-
setting factors for patent eligibility: (1) a claim may not reach to a product of 
nature when the claimed substance is the direct product of a natural law; (2) a 
product that is not markedly different from a naturally occurring form cannot be 
patented; and (3) a claim that preempts all uses of a natural product reaches too far 
and is not patent eligible. See Chakrabarty, 447 U.S. at 303; Funk Brothers Seed 
Co. v. Kalo Inoculant Co., 333 U.S. 127, 130-32 (1948); Gottschalk v. Benson, 409 
U.S. 63, 68 (1972).  
A. The District Court Properly Concluded That Claims-at-Issue Are 
Directed to Pure Products of Nature.  
 
 Constitutional limits on patentability traditionally applied to all inventions, 
including those made in the biological arts.  Chakrabarty, 447 U.S. 303 (1980).  
The Court has held that certain objects created solely by operation of natural law, 
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unaided by the hand of man, are not patentable and “must be free to all mankind” 
in order to encourage innovation.  Id. at 312-13 (“a new mineral or plant 
discovered in the wild would not be patent eligible”).  Despite this well-established 
rule, many inventors have unsuccessfully attempted to circumvent the prohibition 
on patenting naturally occurring objects by arguing the antiquation of the 
fundamental principles of patent law.  See e.g., O'Reilly v. Morse, 56 U.S. 62 
(1853); American Fruit Growers, Inc. v. Brogdex Co., 283 U. S. 1 (1931); Bilski v. 
Kappos, 545 F. 3d 943 (2010).   
Defendants-Appellants attempt to circumvent the rule prohibiting patents on 
products of nature by concealing the simple fact that the BRCA1/2 genes are a 
product of nature beneath a veil of intentionally convoluted technical language. 
However, the district court properly cut through these obfuscations to reach the 
obvious and undisputed conclusion that human genes are products of nature.   
Defendants-Appellants argue that the unique dual nature of genetic 
molecules should be ignored when construing their claims and ask the Court to 
ignore the information concerning the structure of proteins stored within nucleic 
acids.  However, as the district court properly noted, the nature of the information 
storing and transmitting in nucleic acids is critical to properly construe the claims-
in-suit as a whole.  (A215 “Myriad's focus on the chemical nature of DNA, 
however, fails to acknowledge the unique characteristics of DNA that differentiate 
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it from other chemical compounds.”)  Myriad’s claim is analogous to “taking a 
hardback book written by someone else, publishing it in paperback and then 
claiming authorship because the binding is different.”  (A2445.) 
The district court properly identified the “invention” here as information 
already naturally carried within the DNA, while also noting that Defendants-
Appellants’ are in the “genetic information business.”  The district court properly 
held the biological information stored in the “genes” on chromosomes 13 and 16, 
are the products of nature.  As a result, Defendants-Appellants have not created 
anything new, but simply attempted to patent a mere photocopy of naturally 
occurring information.  Therefore, the court properly held that the long-standing 
prohibition on patenting laws of nature forecloses Defendants-Appellants’ claims.  
(A228.) 
The lower court’s decision to limit the scope of patents-in-suit is supported 
by a long line of cases covering patent-eligible subject matter.  Chakrabarty is 
distinct from the case at hand; there, the claim was drawn on newly created 
bacteria different from any other existing organism, and so it was a “product of 
human ingenuity.”  Chakrabarty, 447 U.S. at 309.  Conversely, the court in Funk 
Brothers noted that the invention drawn from a collection of naturally existing 
bacteria produced “no new bacteria” and “no change in the six species of bacteria.”  
Funk Brothers, 333 U.S. at 131.  No transformation occurs in Defendants-
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Appellants’ claims; they involve only the comparison and analysis of two given 
genetic sequences.  (A2479-81; A2574-75.)  Accordingly, in the present case, the 
lower court properly applied the Supreme Court’s clear guidance to identify the 
claims as patent-ineligible because they are directed to preexisting products of 
nature—the information contained within the  BRCA1/2 genes.  
B. Patents-in-Suit Improperly Claim a Naturally Occurring Substance. 
 
The courts have consistently found that naturally occurring substances, even 
when remixed or completely artificially created, are beyond the scope of patent-
eligibility.  In Funk Brothers, a unique mixture of isolated, naturally occurring 
bacteria was beyond the scope of patent-eligibility despite the unique and 
beneficial properties afforded by the new mixture.  Funk Brothers, 333 U.S. at 
130-32.  There, the Court held: “The qualities of these bacteria, like the heat of the 
sun, electricity, or the qualities of metals, are part of the storehouse of knowledge 
of all men.”  Id. at 130.  Similarly, in General Electric, the Federal Circuit found 
that the creation of “substantially pure tungsten” was ineligible subject matter for 
patent protection.  General Electric Co. v. DeForest Radio Co., 28 F.2d 641, 642 
(3d. Cir. 1928).  The mere purification and isolation of the natural substance was 
insufficient to create a markedly different patentable material.  Id.   
Defendants-Appellants’ contention that purified nucleic acids exhibit useful 
properties does nothing to negate the fact that these nucleic acids are not markedly 
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different than those preexisting in nature.  Moreover, the process of purification 
used by Defendants-Appellants does not create a product that is markedly different 
than its naturally occurring form.  It is clear from the undisputed facts determined 
by the lower court that many of Defendants-Appellants’ patents broadly sweep in 
products of nature.  The key to the patents-in-suit is that the claimed nucleic acids 
have genetic information indistinguishable from products of nature. 
 Defendants-Appellants incorrectly rely on Parke-Davis to characterize 
substantially purified nucleic acids as markedly different from natural articles.  
Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95, 103 (S.D.N.Y. 1911).  Instead, 
the district court correctly noted that the ruling regarded the novelty of the subject 
matter in question, not its patent eligibility.  (A207-09.)  Furthermore, the Supreme 
Court and this Courts’ predecessor have rejected the notion that “merely an 
extracted product without change is patentable.”  See Chakrabarty, 447 U.S. at 310; 
Funk Bros., 333 U.S. at 130-32; Am. Fruit Growers, 282 U.S. at 11.  See also In re 
Merz, 97 F.2d 559, 601 (C.C.P.A. 1938); General Electric, 28 F.2d at 642. 
 The claims-at-issue merely restate the natural chemical properties of all 
nucleic acids and are not drawn on any new properties.  Defendants-Appellants’ 
entire model relies on “isolated” and “purified” nucleic acids that carry the same 
biological information of protein translation as nucleic acids that naturally occur in 
human cells.  Hence, the claims-in-suit are drawn on nucleic acids not markedly 
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different than products of nature, and thus properly denied patent protection for 
failing to meet the requirements of 35 U.S.C. § 101.  (A228.) 
III.    CLAIMS-AT-ISSUE IMPROPERLY PREEMPT ALL OTHER USES 
OF THE UNDERLYING PRINCIPLE  
 
  The Supreme Court has held that a process preempting every practical use 
of a fundamental principle may not be patented.  Gottschalk, 409 U.S. at 72.  There, 
the patent covered a process performed entirely on a computer, which converted 
binary-coded decimals into pure binary numbers.  Despite the technical complexity 
of the underlying process, the Court held that to grant a patent for this invention 
“would preclude any further use of the algorithm.” Id.  
For over one-hundred-fifty years, the Court has found that complete field 
preemption, in any area, is evidence of a patent claim drawn on ineligible subject 
matter.  See O’Reilly v. Morse, 56 U.S. 62 (1854) (invention claiming all uses of 
electro magnetism [sic] was patent-ineligible as it precluded all possible uses of a 
field); Corning v. Burden, 94 U.S. 780 (1854) (chemical process or physical acts 
must confine the patent-monopoly within rather definite bounds); but see Diamond 
v. Deihr, 50 U.S. 175 (1981) (computer programmed to use the Arrhenius equation 
to control a process for curing rubber was patent eligible as it did not preclude any 
other use of the Arrhenius equation).  Regardless of the underlying technology, 
patents that preclude any other use of a field are suspect.  Deihr, 50 U.S. at 187-88.   
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In the present case, the lower court correctly identified the field-at-issue to 
be a test for the presence of BRCA1/2 genes.  The claims-at-issue cover the entire 
field of use for BRCA1/2 genes and, under the principle of complete field 
preemption, are drawn on patent ineligible subject matter. 
          A. The BRCA Claims-at-Issue Prevent Further Life-Saving Research. 
 
Gene patents have resulted in negative effects on the progress of research 
and biotechnology.  A recent study found that thirty-percent of clinical laboratories 
reported voluntarily stopping development on a test for a haemochromatosis-
related gene once a patent was issued for it.  Matthew Herder, Patents & The 
Progress of Personalized Medicine: Biomarkers Research as Lens, 18 Ann. Health 
L. 187, 209-211 (2009).  Another study, conducted by Dr. Mildred Cho, found that 
fifty-three percent of laboratory directors in the United States decided not to 
develop a new clinical test because of a gene patent or license, and sixty-seven 
percent believed that gene patents decreased their ability to conduct research.  
(A2672-73.) 
In this case, several medical researchers cited Defendants-Appellants’ 
patents as hindering or completely barring their research on breast cancer.  (See, 
e.g., A2650; A2753; A2775; A2813; A2828; A2848-50; A2887-91; A2934-36; 
A2978-81; A3022; A3035-36.)  Unlike many other patents, the patents-in-suit are 
essentially impossible to invent around.  See Isabelle Huys, et. al., Legal 
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Uncertainty in the Area of Genetic Diagnostic Testing, 27 Nature Biotechnology 
903, 907 (2009) (describing Myriad Patent 6,033,857 as a “blocking patent” and 
claims 1-8 as “almost impossible to circumvent.”)  The claims-at-issue are 
especially detrimental to breast cancer research because unlike pharmaceutical 
patents, the BRCA1/2 patents completely foreclose research on any effects of the 
BRCA1/2 genes.  (A153; A2448-49; A2646-49; A2652-53; A2672-75; A2775-78; 
A2937-39; A2980-83; A3037-39; A3068; A3080; A3085.)  With the claims-at-
issue, researchers cannot conduct any research, innovation, or development of the 
naturally occurring gene.  For example, as a result of the patents, researchers 
cannot develop more efficient or expansive tests that cover mutations that 
Defendants-Appellants have not yet identified.  (A39; A2649-50; A3068; A3080; 
A3085.) 
 The Department of Health and Human Services established a commission to 
study the effects of gene patents on medical research and patient access to genetic 
tests. Sec’y’s Advisory Comm. On Genetics, Health and Soc’y, Gene Patents and 
Licensing Practices and Their Impact on Patient Access to Genetic Tests (2010) at 
16, available at http://oba.od.nih.gov/oba/sacghs/reports/ 
SACGHS_patents_report_2010.pdf (“SACGHS”).  SACGHS found stirring 
evidence that gene patents can harm genetic research by hindering vital follow-up 
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projects.  Id. at 17.  Patents-in-suit were found to have led directly to a decrease in 
information available to the public of these breast cancer genes.  (A163.)  
Finally, a recent study by the Department of Biostatistics and Bioinformatics 
at Duke University found that some claims of the patents-in-suit would broadly 
preempt a range of current genetic tests, including tests not directly linked to 
BRCA1/2 research.  Thomas B. Kepler, et al., Metastatasizing patent claims on 
BRCA1, Genomics May 2010. available at http://www.elsevier.com 
/framework_products/promis_misc/kepler_crossman_cook_deegan.pdf  (last 
accessed Dec. 1, 2010).  One example is dependent claim 5 of patent-in-suit 
5,747,282.  This claim broadly covers “an isolated DNA having at least 15 
nucleotides of the DNA of claim 1.”  Id. at 2.  Although Defendants-Appellants 
claim the fifteen nucleotides that occur on the BRCA1/2 genes, these nucleotide 
sequences also occur elsewhere in the genome.  Id. at 3.  Thus, the patents-in-suit 
give Defendants-Appellants control over diagnostic testing for diseases which they 
performed no research or work.  (A2447.)  Researchers and medical professionals 
around the world routinely sequence Genes and the particular complete field 
preemption presented by these claims is alarming.   
B. The Preclusion of Additional Research by the Claims-at-Issue 
Detrimentally Affects Patients. 
 
The claims-at-issue preclude scientific research and have a detrimental effect 
on patient health. SACGHS at 17.  While Defendants-Appellants tout their test as 
 17 
the “gold standard,” it competes in a field of just one: its own monopoly.  (A157.)  
This monopoly remains unhealthy for the public; a recent study conducted at the 
University of Washington found the test had a twelve-percent error rate.  Tom 
Walsh, et. al., Spectrum of Mutations in BRCA1, BRCA2, CHECK2, and TP53 in 
families at High Risk of Breast Cancer, 295 JAMA 1369, 1386 (2006) (12% of the 
300 people examined from high risk families had mutations that the Myriad tests 
missed). This error rate may, in fact, be understated as Defendants-Appellants’ 
monopoly over research on BRCA1/2 has resulted in a great disparity in the 
effectiveness of their test when applied to women of non-European ancestry.  
(A1059; A3205-06.) 
For patients who must make major life altering decisions based on a single 
flawed test, such as Plaintiff-Appellee Limary, among others, the issue of total 
field preemption is not a mere application of patent law theory.  (A105-07.)  
Defendants-Appellants’ complete control of the BRCA1/2 genes has prevented 
researchers, such as Plaintiff-Appellee Dr. Cho, from offering a second opinion on 
the results of BRCA1/2 tests or from offering lower-cost tests to women who 
cannot afford the monopolistic and often non-insured pricing of Defendants-
Appellants’ test.  (A2670-75.)  Plaintiff-Appellee American Association of 
Medical Pathologists is deeply concerned that Defendants-Appellants’ patents 
require patients be provided with a knowingly flawed test.  As a result, Plaintiffs-
 18 
Appellees cannot use their considerable expertise to provide patients with any 
alternative or validity testing. (A36-46; A1034-36.)  UAEM has related concerns 
that university researchers cannot access and use the basic facts about these genes 
to enhance the public good through further research and development. 
C. Other Nations Have Also Refused to Accept Defendants-Appellants’ 
Patent Claims. 
 
The purpose of the patent system is to encourage innovation by promoting 
the progress of science and useful arts.  U.S. CONST., art. 1, § 8, cl. 8.  In analyzing 
the preemptory effects of Defendants-Appellants’ patents, it is useful to compare 
the experience of researchers and medical doctors under different patent regimes.  
The European Union, largely in response to the restrictive licensing policies by 
Defendants-Appellants, prohibit the enforcement of patents that would prevent 
research.  SACGHS at 99.  Additionally, individual European nations have refused 
to honor the enforcement of Defendants-Appellants’ patents and allowed market 
forces to develop less costly tests.  (A3207-08.)  While market forces foster the 
development of comprehensive, affordable and less costly BRCA testing in Europe, 
Canada, and Australia, U.S. patients must rely on an expensive test with an 
unacceptably high failure rate, especially when it comes to the analysis of the 
genome belonging to women of color.  
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CONCLUSION 
 For over 150 years, the U.S. Supreme Court has held that laws of nature, 
products of nature, and abstract ideas are ineligible for patent protection.  The 
patent claims by Defendants-Appellants are clearly directed at basic products of 
nature and therefore ineligible for patent protection. Additionally, they preempt all 
uses of a natural product. 
For the above-stated reasons, the Court should uphold the decision of the 
district court and find that the USPTO improperly granted the Defendants-
Appellants’ patent claims.   
     Respectfully submitted, 
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